Screening for NAFLD in Flanders

Non-Alcoholic Fatty Liver Disease Clinical Trial

Official title:

Screening for Non-Alcoholic Fatty Liver Disease (NAFLD) in a General Practitioner Population, in Flanders, Belgium.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04647409
• Other study ID #: SCREEFLAN-01
• Status: Recruiting
• Phase: N/A
• Start date: October 26, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: Hasselt University
• Contact: Geert Robaeys, prof. dr.
• Phone: +32 89 32 65 05
• Email: geert.robaeys[@]zol.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the Belgian adult population more than half, and numbers are still increasing, of the population is overweight or obese. These people are at risk to develop NAFLD. However, we lack epidemiological data in Belgium. Therefore, it is important to do epidemiological studies to investigate NAFLD prevalence and disease severity based on a non-invasive approach and evaluate how patients are to be referred.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older,
• able to understand Dutch,
• able to understand the informed consent

Exclusion Criteria:

• secondary causes of steatosis
• excessive alcohol abuse

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease

Intervention

Other:
• screening
The determination of the prevalence of NAFLD in a general population in Flanders, Belgium

Locations

Country	Name	City	State
Belgium	Hasselt University	Hasselt

Sponsors (1)

Lead Sponsor	Collaborator
Hasselt University

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CLDQ-NAFLD	The determination of the prevalence of NAFLD in a general population in Flanders, Belgium by using A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis	baseline
Primary	36-Item Short Form Survey (SF-36)	SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and are now widely utilized by managed care organizations and by Medicare for routine monitoring and assessment of care outcomes in adult patients.	baseline